首页> 外文期刊>Journal of thrombosis and haemostasis: JTH >Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.
【24h】

Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.

机译:FVIII在血友病患者中成功通过FVIII诱导免疫耐受,而没有FVIII特异性T细胞缺失的情况下,可能会发生。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The development of an inhibitor is the major complication facing patients with hemophilia A treated by administration of factor (F) VIII concentrates. Restoration of tolerance to FVIII can be achieved by prolonged administration of FVIII (immune tolerance induction, ITI). Although ITI has been used for more than 30years in patients with hemophilia A and inhibitor, its mechanism of action is still poorly understood. OBJECTIVES: As administration of high doses of antigen can induce the apoptosis of the T cells recognizing the antigen, a potential mechanism of action of ITI may be the deletion of FVIII-specific T cells. PATIENTS/METHODS: We studied the CD4+ T-cell response to FVIII in five (one mild, one moderate and three severe) patients successfully desensitized by administration of FVIII and in control subjects. RESULTS: Following repeated stimulation with autologous dendritic cells loaded with FVIII, FVIII-specific T oligoclonal cell lines were expanded from the blood of one of the successfully desensitized patients. The FVIII-specific T cells produced IL-5, IL-13 and IL-2. By contrast, FVIII-specific T-cell lines could not be derived from three patients with mild hemophilia A without inhibitor or from four normal control subjects. CONCLUSIONS: These data represent the first analysis of the cellular mechanisms regulating the induction of tolerance to FVIII. They demonstrate that successful tolerance induction may occur without deletion of FVIII-specific T cells.
机译:背景:抑制剂的开发是通过给予因子(F)VIII浓缩物治疗的血友病A患者面临的主要并发症。恢复FVIII的耐受性可以通过延长FVIII的给药(免疫耐受诱导,ITI)来实现。尽管ITI已在甲型血友病和抑制剂患者中使用了30多年,但其作用机理仍知之甚少。目的:由于给予高剂量抗原可诱导识别该抗原的T细胞凋亡,因此ITI的潜在作用机制可能是FVIII特异性T细胞的缺失。患者/方法:我们研究了五名(轻度,一名中度和三名严重)因接受FVIII脱敏而成功治疗的FVIII患者和对照组的CD4 + T细胞对FVIII的应答。结果:在用载有FVIII的自体树突状细胞反复刺激后,从一名成功脱敏患者的血液中扩增了FVIII特异性T寡克隆细胞系。 FVIII特异性T细胞产生IL-5,IL-13和IL-2。相比之下,FVIII特异性T细胞系不能来自三名没有抑制剂的轻度A型血友病患者或四个正常对照组。结论:这些数据代表了对诱导FVIII耐受性的细胞机制的首次分析。他们证明成功的耐受诱导可能会发生,而不会缺失FVIII特异性T细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号